Acute Hepatic Porphyria Drugs Market Trends

 Growth Drivers

Increasing Prevalence of Rare Metabolic and Genetic Disease to Boost the Market Growth

Since the incidence rate of rare metabolic disorders such as acute hepatic porphyria have been growing in the past few year, the demand for acute hepatic porphyria treatment is increasing. According to U.S. National Library of Medicines (Genetic Home Reference), the prevalence of porphyria ranges from 1 in 500 to 1 in 50,000 people worldwide and acute intermittent porphyria (AIP) is the most common form of acute hepatic porphyria in most countries. This is anticipated to significantly expand the acute hepatic porphyria treatment market.

Expanding Healthcare R&D and Increase in Awareness to Drive the Market Growth

The expanding growth in pharmaceutical as well as biotechnology industries all over the world is improving at a fast pace owing to the increasing number of cases of various diseases. Further, there is an increased awareness among people regarding acute hepatic porphyria owing to the fact that it primarily affects the nervous system and other major organs. The growing research and development for better treatment methods at research laboratories further fuels the healthcare industry. On the back of these, the market is predicted to grow over the forecast period. 

Challenges

High Treatment Costs and Lack of Reimbursement Facilities to Hamper the Market Growth

Despite the improving healthcare infrastructure, there is a high cost associated with this drug used for the treatment of this disease. In addition to this, the poor reimbursement policies in the developing countries is estimated to hinder the growth of acute hepatic porphyria treatment market in the future.